Trial Search Results

Safety and Efficacy of Exendin 9-39 in Patients With Postbariatric Hypoglycemia

This clinical study will evaluate whether taking an investigational drug called exendin 9-39 is safe, well-tolerated, and helps to prevent low blood sugar in people who have had bariatric surgery and later develop a rare condition called postbariatric hypoglycemia (PBH).

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Eiger BioPharmaceuticals

Stanford Investigator(s):

Intervention(s):

  • Drug: exendin 9-39
  • Other: Placebo

Phase:

Phase 2

Eligibility


Inclusion Criteria:

   - Body mass index (BMI) of up to 40 kg/m2

   - Roux-en-Y gastric bypass (RYGB) surgery performed ≥12 months prior

   - Diagnosis of PBH

   - At least 2 episodes during screening 2-week run-in phase of severe hypoglycemia

Exclusion Criteria:

   - Other cause of endogenous hyperinsulinism other than PBH

   - Metabolic or bariatric surgical procedure other than RYGB

   - History of non-RYGB upper GI surgery

   - Use of agents that may interfere with glucose metabolism

Ages Eligible for Study

18 Years - 65 Years

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Aileen Muno
(650) 725-9890
Not Recruiting